BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38416506)

  • 21. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease.
    Kurosawa S; Oshima K; Yamaguchi T; Yanagisawa A; Fukuda T; Kanamori H; Mori T; Takahashi S; Kondo T; Kohno A; Miyamura K; Umemoto Y; Teshima T; Taniguchi S; Yamashita T; Inamoto Y; Kanda Y; Okamoto S; Atsuta Y
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1749-1758. PubMed ID: 28669922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
    Palmer J; Williams K; Inamoto Y; Chai X; Martin PJ; Tomas LS; Cutler C; Weisdorf D; Kurland BF; Carpenter PA; Pidala J; Pavletic SZ; Wood W; Jacobsohn D; Arai S; Arora M; Jagasia M; Vogelsang GB; Lee SJ
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):337-44. PubMed ID: 24315845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported treatment response in chronic graft-
    Im A; Pusic I; Onstad L; Kitko CL; Hamilton BK; Alousi AM; Flowers ME; Sarantopoulos S; Carpenter P; White J; Arai S; El Jurdi N; Chen G; Cutler C; Lee S; Pidala J
    Haematologica; 2024 Jan; 109(1):143-150. PubMed ID: 37226713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported symptom burden and impact on daily activities in chronic graft-versus-host disease.
    Yu J; Hamilton BK; Turnbull J; Stewart SK; Vernaya A; Bhatt V; Meyers O; Galvin J
    Cancer Med; 2023 Feb; 12(3):3623-3633. PubMed ID: 36394207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial reconstitution of cutaneous microvessels in long-term survivors after allogeneic bone marrow transplantation.
    Haeusermann P; Kump E; Rovó A; Tichelli A; Itin P; Gratwohl A; Biedermann BC
    Dermatology; 2009; 219(1):32-41. PubMed ID: 19407437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.
    Shaw BE; Brazauskas R; Millard HR; Fonstad R; Flynn KE; Abernethy A; Vogel J; Petroske C; Mattila D; Drexler R; Lee SJ; Horowitz MM; Rizzo JD
    Cancer; 2017 Dec; 123(23):4687-4700. PubMed ID: 28817182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].
    Huang SQ; Huang RH; Quan Y; Wang FM; Cheng XJ; Wang XQ; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):54-61. PubMed ID: 38527839
    [No Abstract]   [Full Text] [Related]  

  • 30. Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease.
    Sorenson E; McAndrew R; Patel V; Logan AC; Koo J; Levin E
    JAMA Dermatol; 2015 Jun; 151(6):635-7. PubMed ID: 25806783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation.
    Zhou Y; Barnett MJ; Rivers JK
    Arch Dermatol; 2000 Jun; 136(6):717-21. PubMed ID: 10871932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
    Merkel EC; Mitchell SA; Lee SJ
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life.
    Kurosawa S; Yamaguchi T; Oshima K; Yanagisawa A; Fukuda T; Kanamori H; Mori T; Takahashi S; Kondo T; Kohno A; Miyamura K; Umemoto Y; Teshima T; Taniguchi S; Yamashita T; Inamoto Y; Kanda Y; Okamoto S; Atsuta Y
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1851-1858. PubMed ID: 31129353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frailty in Patients with Chronic Graft-versus-Host Disease.
    Rashid N; Arora M; Jurdi NE; Onstad L; Pidala JA; Flowers ME; Lee SJ
    Transplant Cell Ther; 2023 Jun; 29(6):367-374. PubMed ID: 36921916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
    DeFilipp Z; Alousi AM; Pidala JA; Carpenter PA; Onstad LE; Arai S; Arora M; Cutler CS; Flowers MED; Kitko CL; Chen GL; Lee SJ; Hamilton BK
    Blood Adv; 2021 Oct; 5(20):4278-4284. PubMed ID: 34521116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity.
    Kaffenberger BH; Zuo RC; Gru A; Plotner AN; Sweeney SA; Devine SM; Hymes SR; Cowen EW
    J Am Acad Dermatol; 2014 Oct; 71(4):745-53. PubMed ID: 24993601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101.
    El Jurdi N; Martens MJ; Brunstein CG; O'Donnell P; Lee SJ; D'Souza A; Logan B; Hong S; Singh AK; Sandhu K; Shapiro RM; Horowitz MM; Hamilton BK
    Transplant Cell Ther; 2023 Jul; 29(7):467.e1-467.e5. PubMed ID: 37088401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.